Skip to main content
. Author manuscript; available in PMC: 2014 Jan 23.
Published in final edited form as: Nature. 2001 Sep 13;413(6852):165–171. doi: 10.1038/35093109

Figure 1.

Figure 1

EL4 and B16-BL6 tumor cells expressing NKG2D ligands are rejected by NK cells in syngeneic mice. C57BL/6 or B6-Rag1−/− mice were treated with the indicated antibodies before inoculation with the indicated number of EL4 (a, b) or B16-BL6 (c-e) tumor cell transductants. Tumor growth was monitored thereafter. Data are representative of at least three experiments. f, g, B6 mice were injected i.v. with 3×105 B16-BL6 transductants. Lung metastases were counted two weeks after the tumor challenge (f) or the lung lobes from representative mice in a separate experiment were examined three weeks after tumor challenge (g).